Beraprost

Beraprost

Beraprost
Systematic (IUPAC) name
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-
methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-
5-butanoic acid
Clinical data
AHFS/Drugs.com
Legal status
  • ?
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 50–70%
Metabolism Unknown
Biological half-life 35–40 minutes
Excretion ?
Identifiers
CAS Registry Number  YesY 88475-69-8
ATC code B01
PubChem CID:
IUPHAR/BPS
ChemSpider  YesY
UNII  YesY
ChEMBL  N
Chemical data
Formula C24H30O5
Molecular mass 398.492 g/mol
 N   

Beraprost is a synthetic analogue of prostacyclin, under clinical trial for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology

As an analogue of prostacyclin PGI2, beraprost affects vasodilation, which in turn lowers blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill available in strength of 20 mcg. Dose ranges from 60 to 180 mcg in divided doses after meals.